CClinicalTrials.gg
Active, not recruitingNCT06491758ABVN2Updated Mar 6, 2026

ABVN Phase 2-Studying the Effect of Stimulation on the Auricular Branch of the Vagal Nerve

An interventional study of ML1101 Stimulus Isolator and Vagal Maneuver in Gastroparesis, sponsored by Indiana University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Jun 2020, registered Jun 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
131
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to find out if we can gain access to the vagus nerve which is largely an internal nerve that controls stomach function. We hope to gain access to the internal vagus nerve by electrically stimulating the nerve around the external ear. If we can do this then we hope that this will help our treatment of patients with nausea and vomiting and disordered stomach function

Read the detailed description

Subjects will undergo transcutaneous stimulation of the auricular branch of the vagus nerve and also undergo blood draw before, after stimulation and later a third draw after a period of no stimulation. Healthy subjects will also undergo vagal maneuver using the Multi Array Electrodes (MEA). Gastroparetic subjects will also undergo vagal maneuver using either the regular EKG electrodes or the MEA electrodes.

Subjects will also complete health history questionnaires.

02

Conditions studied

  • Gastroparesis

Browse trials for

03

In context

Gastroparesis

307 studies on the registry are indexed under Gastroparesis; 68 are open to participants now.

This study's enrollment of 131 is above the median of 44 across 202 interventional studies indexed under Gastroparesis.

Browse Gastroparesis studies →

Lead sponsor

Indiana University is the lead sponsor of 958 studies on the registry; 200 are open to participants now.

Of its 142 completed or terminated interventional studies of FDA-regulated products, 112 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria healthy volunteers

  • Healthy volunteers with no gastric symptoms or conditions (except due to COVID 19)
  • Aged 18-80 years
  • Willing to have electrodes placed in the external ear (ABVN arm)
  • Willing to perform vagal activity maneuver (Vagal arm)
  • Willing to have 1 tablespoon (15 ml) of blood drawn at 3 time points

Inclusion Criteria gastroparesis subjects

  • Gastroparesis subjects with a confirmed diagnosis of gastroparesis from a GI physician
  • Have a formal diagnosis of gastroparesis or are seeing the GI physician for symptoms related to gastroparesis
  • Aged 18-80 years
  • Willing to have electrodes placed in the external ear (ABVN arm)
  • Willing to perform vagal activity maneuver (Vagal arm)
  • Willing to have 1 tablespoon (15 ml) of blood drawn at 3 time points

Exclusion Criteria:

  • Unable to provide consent
  • Pregnant females
  • Prisoners
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Healthy Subjects

    Subjects who have no gastric symptoms or conditions

    Device: ML1101 Stimulus Isolator · Procedure: Vagal Maneuver

  • Experimental
    Gastroparesis Subjects

    Subjects with a confirmed diagnosis of gastroparesis.

    Device: ML1101 Stimulus Isolator · Procedure: Vagal Maneuver

Interventions

  • DeviceML1101 Stimulus Isolator

    Electrical stimulation electrodes will be placed on the ear with the intensity of the current being increased by 10 percent every 60 seconds, the subject will grade the intensity of the current on a scale of 0-10. Increasing of the current will occur until the subject reports a comfortable level. Once the target level has been achieved the stimulation will be delivered for 2 minutes.

  • ProcedureVagal Maneuver

    Subjects will undergo the following procedures to stimulate the vagus nerve. * Cough: 6 to 8 forceful coughs * Cold stimulus: a washcloth soaked in ice water will be placed on the face for 10 seconds. * Carotid massage * Gagging: a tongue depressor will be inserted for 10 seconds into the mouth touching the back of the mouth. * Valsalva maneuver: subjects will will be asked to bear down as if they were having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a machine that measures how hard they are blowing. * Eating: Subjects will be asked to drink water ( 8oz or 1 cup) or/ and Ensure Original ( 8 oz or 1 cup) that has 220 calories after fasting overnight to see that effect on vagal activity during eating.

06

What researchers measure

Primary outcomes

  1. Amplitude of vagal nerve compound action

    To measure the amplitude of vagal nerve compound action potentials during stimulation of the auricular branch of the vagal nerve and during vagal maneuvers.

    Time frame: 3 hours

  2. Respiratory Changes in heart rate during stimulation

    To measure respiratory changes in heart rate during stimulation of the auricular branch of the vagal nerve and also during the vagal maneuvers phase.

    Time frame: 3 hours

  3. Changes in amplitude of the surface electrogastrogram

    To measure the changes of surface electrogastogram during stimulation of the auricular branch of the vagal nerve and also during the vagal maneuvers phase.

    Time frame: 3 hours.

  4. Changes in gastric hormones

    To measure the effect of stimulation of the auricular branch of the vagal nerve and/or of vagal maneuvers on gastric hormones.

    Time frame: 3 hours.

07

Study locations

1 site
  • Indiana University
    Indianapolis, Indiana 46202, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data may be shared with other researchers for similar purposes as to this study

Supporting information: Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06491758
Lead sponsor
Indiana University
Responsible party
Thomas V. Nowak (Professor, Indiana University) — Principal investigator
First posted
Jul 9, 2024
Start date
Jun 2, 2020
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Mar 6, 2026

Study contacts

Thomas V Nowak, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion